Assembly Biosciences Inc. (ASMB)
undefined
undefined%
At close: undefined
15.38
0.20%
After-hours Dec 13, 2024, 03:59 PM EST

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.

The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection.

It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC.

The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.

Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences Inc.
Assembly Biosciences Inc. logo
Country United States
IPO Date Dec 17, 2010
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Jason A. Okazaki

Contact Details

Address:
331 Oyster Point Boulevard
South San Francisco, California
United States
Website https://www.assemblybio.com

Stock Details

Ticker Symbol ASMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001426800
CUSIP Number 045396108
ISIN Number US0453962070
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Jason A. Okazaki Chief Executive Officer, President & Director
Amy Figueroa C.F.A. Investor Relations Consultant
Dr. Adam Zlotnick Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Dr. Anuj Gaggar M.D., Ph.D. Chief Medical Officer
Dr. Nicole S. White Ph.D. Chief Manufacturing Officer
Dr. Uri A. Lopatin M.D. Co-Founder and Clinical & Scientific Advisor
Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer
Jeanette M Bjorkquist Executive Director of Accounting & Treasury
Jennifer A. Troia MHROD, SHRM-SCP, SPHR Chief Human Resources Officer
Thomas E. Rollins Executive Officer

Latest SEC Filings

Date Type Title
Nov 26, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 07, 2024 8-K Current Report
Nov 07, 2024 424B5 Filing
Nov 07, 2024 10-Q Quarterly Report
Nov 07, 2024 8-K Current Report
Oct 09, 2024 4 Filing
Oct 04, 2024 4 Filing
Oct 04, 2024 4 Filing